Search

To determine whether there is a temporal association between arthritis and uveitis activity among children with juvenile idiopathic arthritis-associated uveitis (JIA-U).Uveitis and arthritis data from patients with JIA-U age ≤21 years were collected from July 2013 to December 2019 at a tertiary care center. Arthritis activity was assessed at each rheumatology visit, and the primary outcome was the presence of active uveitis at ophthalmologic examination within 45 days of the rheumatology visit. Repeated-measures logistic regression was used to evaluate the temporal association between any uveitis activity within 45 days of arthritis activity. Models were adjusted for demographic-, disease-, and treatment-related factors.A total of 98 patients were included: 81 (83%) female, 67 (69%) antinuclear antibody positive, 59 (60%) oligoarticular, and 13 (13%) enthesitis-related arthritis (ERA) subtypes. There were 1,229 rheumatology visits, with a median of 13 visits per patient (interquartile range 7-18). Concordance between arthritis and uveitis activity was observed 73% of the time (694 of 947). There was an independent temporal association between uveitis and arthritis activity (odds ratio 2.47 [95% confidence interval 1.72-3.54]; P 0.01), adjusted for demographic and disease characteristics. Use of combination biologic and nonbiologic disease-modifying antirheumatic drugs, female sex, HLA-B27 positivity, and ERA and polyarticular (rheumatoid factor negative) subtypes were associated with decreased odds of active uveitis at any time point.In patients with JIA-U, there is a significant temporal association between arthritis and uveitis disease activity. These novel results suggest that an arthritis flare should prompt an expedited referral to the ophthalmologist.

PURPOSE: Community-academic partnerships have the potential to improve access to clinical trials for under-represented minority patients who more often receive cancer treatment in community settings. In 2017, the Memorial Sloan Kettering (MSK) Cancer Center began opening investigator-initiated clinical trials in radiation oncology in targeted community-based partner sites with a high potential to improve diverse population accrual. This study evaluates the effectiveness of a set of implementation strategies for increasing overall community-based enrollment and the resulting proportional enrollment of Hispanic patients on trials on the basis of availability in community-based partner sites. METHODS: An interrupted time series analysis evaluating implementation strategies was conducted from April 2018 to September 2021. Descriptive analysis ofHispanic enrollment on investigator-initiated randomized therapeutic radiation trials open at community-based sites was compared with those open only at themain academic center. RESULTS: Overall, 84 patients were enrolled in clinical trials in the MSK Alliance, of which 48 (56%) identified as Hispanic. The quarterly patient enrollment pre- vs postimplementation increased from 1.39 (95% CI, –3.67 to 6.46) to 9.42 (95% CI, 2.05 to 16.78; P5 .017). In the investigator-initiated randomized therapeutic radiation trials open in the MSK Alliance, Hispanic representation was 11.5% and 35.9% in twometastatic trials and 14.2% in a proton versus photon trial. Inmatched trials open only at the main academic center, Hispanic representation was 5.6%, 6.0%, and 4.0%, respectively. CONCLUSION: A combination of practice-level and physician-level strategies implemented at community-based partner sites was associated with increased clinical trial enrollment, which translated to improved Hispanic representation. This supports the role Q:2 of strategic community-academic partnerships in addressing disparities in clinical trial enrollment.

Groups historically underrepresented in medicine also remain underrepresented within ophthalmology. Prospective applicants, in particular women and racial and ethnic minority groups, consider program factors related to gender diversity, ethnic diversity, and program culture more than nonminority groups. A prospective applicant's decision to apply to a particular residency program may be influenced by the information presented on the program's website.To evaluate for presence of diversity or inclusion information on US ophthalmology program websites.This quality improvement study, conducted from May 1 to June 2, 2021, included a cross-sectional review of ophthalmology program websites. Ophthalmology program websites were reviewed for the presence of 6 predetermined diversity or inclusion information criteria.The presence of 6 predetermined diversity or inclusion information criteria. Association between program size and ranking with presence of diversity or inclusion information criteria was assessed.Of the 121 US program websites reviewed, 29 (24%) met at least 1 of the 6 predetermined criteria. Programs with more than 12 residents (odds ratio [OR], 3.58; 95% CI, 1.39-9.55; P = .004) and programs ranked within the top 20 best hospitals for ophthalmology (OR, 3.28; 95% CI, 1.05-10.1; P = .02) were more likely to have at least 1 of the diversity or inclusion information criteria on their website.Results of this quality improvement study suggest that the majority of US ophthalmology residency programs do not have information regarding diversity or inclusion on their websites. Although this investigation cannot determine how an ophthalmology residency program's website reflects the diversity and inclusion within the program, these findings suggest that there is a gap in the information that prospective applicants can collect when evaluating ophthalmology residency program websites.